Tokyo, Japan – February 18, 2020 – LPIXEL Inc., a leader in image analysis and processing in life science and medical research, announced today the submission of its application to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for “EIRL Chest X-ray Lung nodule (tentative name),” LPIXEL’s medical image analysis software that identifies findings suggestive of lung nodules from chest X-rays to support doctors in the scan reading process. From reducing the risks of overlooking lesions to providing high quality care, approval of this solution is anticipated to make a significant contribution to enhancing the efficiency of medical care delivery.
About Lung Nodules
In a typical X-ray, air appears black, while bones, muscle, blood and other fluids appear white. Lung nodules also appear as white spots on the X-ray, but in areas that should normally be black. Patients with these findings can be suspected of having lung cancer, tuberculosis or pneumonia. If lung nodules are found during routine health programs, patients are required to perform additional tests.
Background
Cancer is the leading cause of death in Japan, with lung cancer causing the highest number of mortalities¹. Early detection and treatment are indispensable for improving survival rates, and for this reason, patients are undergoing routine screenings and health examinations. However, relative to the number of scans, there are not enough doctors who can read and interpret all of the X-rays. With a pressing need to reduce overlooked lesions and to promote workplace reforms in the medical space, healthcare providers are strongly encouraged seek advances to provide efficient, high quality medical care.
[1]Cancer Registry and Statistics (2017). Cancer Information Service, National Cancer Center, Japan
About EIRL
EIRL is the collective name given to LPIXEL’s AI medical image diagnostic support technology. LPIXEL aims to provide solutions that enable more efficient, accurate diagnosis by implementing its unique algorithms to analyze medical data, such as brain MRI, chest X-rays, and colonoscopy. In October 2019, LPIXEL announced the PMDA approval of “EIRL aneurysm,” which is its deep learning solution for detecting brain aneurysms from brain MRI. EIRL aneurysm is Japan’s first deep-learning powered software as a medical device (SaMD) to be approved by the PMDA.
About LPIXEL
LPIXEL is a leader in advanced image analysis and processing technology encompassing the life science field. Founded in March 2014, LPIXEL is dedicated to offering research facilities top-tier image analysis technologies and medical diagnosis technologies, both of which adopt advanced AI technology. The company is currently working in collaboration with the University of Tokyo Hospital, the National Cancer Center Japan and other research institutions to further the development of its AI-based medical diagnosis technology. For more information, please visit https://lpixel.net/en/.
Contact Information
LPIXEL Inc.
TEL：03-6259-1713 Email：pr@lpixel.net
